CLINIPRO - Lipocryo Wins Major European Legal Case For Patent Nullity - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
CLINIPRO - Lipocryo Wins Major European Legal Case For Patent Nullity


CLINIPRO - Lipocryo Wins Major European Legal Case For Patent Nullity

PR Newswire

BARCELONA, June 2, 2014 /PRNewswire/ --

The sentence rejects completely the lawsuit promoted by ZELTIQ and confirms the nullity of its patents. 

 

The Provincial High Court in Barcelona Section 15 dictated a resolution, dated May 15 th 2014, fully dismissing the ZELTIQ Aesthetics Inc. appeal of the sentence dated January 25 th, 2013, confirming that the patents of the plaintiffs are null ifi ed, due to the lack of inventive activity (the procedure patent) and to the lack of new items (the device patent).

Thus, the lawsuit promoted by ZELTIQ for an alleged infringement of patents against CLINPRO, a Spanish company that manufactures medical-aesthetical devices, has not only been rejected once more, but has confirmed that these patents are invalid.  

This is the logical end of the process begun on June 25 th 2012, when cautionary measures against Clinipro, issued May 5 th 2012, were declared without effect and continued with the resolution of the Barcelona Trade Court No. 5, dated January 25 th 2013, disregarding the ZELTIQ lawsuit against CLINIPRO.

Philippe Plan, CLINIPRO CEO, has stated: "The confirmation of ZELTIQ-MGH patents' invalidity, added to the worldwide success of LipoCryo and the new lipocryolysis evolution system, LipoContrast, definitively encourage us to focus our next input to the American market."

The case, undertaken by the specialized firm SOL MUNTAÑOLA ABOGADOS from Barcelona, has lasted for more than two years, since ZELTIQ Aesthetics Inc. first filed its application for interim measures, until today, when CLINIPRO's arguments have been confirmed.

About CLINIPRO 

CLINIPRO is a company with presence in over 40 countries and its vision is to remain the benchmark of effective, secure and non-invasive alternatives to surgical treatments of aesthetic medicine. CLINIPRO always aims to offer the latest technology and stay ahead of market trends, to provide the most innovative technologies. With more than 20 years of industry experience, CLINIPRO has professional technicians and highly qualified physicians that support their brands, such as, among others, LipoCryo or the new LipoContrast, one step beyond lipocryolysis, which contribute to people's physical well being through safe and effective procedures.

More information
Fermín San Martín
fsanmartin@clinipro.net
+34-935-903-108

SOURCE CLINIPRO

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
7%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here